November 22, 2021
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India
September 01, 2021
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death by 21 percent, in adult patients of heart failure with preserved ejection fraction, with or without diabetes
June 15, 2021
Dr. V. Mohan Releases 9-point Action for People with Diabetes
May 26, 2021
Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine
May 18, 2021
Boehringer Ingelheim allocates COVID relief fund to support underserved communities and patients in India
March 25, 2021
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management
January 11, 2021
Boehringer Ingelheim announces appointment of Vani Manja as India Country MD
Media Contacts
Director, Communications, Boehringer Ingelheim India
Senior Manager, Communications, Boehringer Ingelheim India